

# Renal Cell Carcinoma Follow-Up Report

## Patient Information

**Name:** Lucas Ramirez  
**DOB:** March 10, 1969  
**Email:** lucas.ramirez@example.com  
**Allergies:** None  
**Medical Record Number:** 667788

## Appointment Details

**Date:** June 28, 2024  
**Time:** 3:30 PM  
**Doctor:** Dr. Emma Foster, MD

## Chief Complaint

Follow-up for renal cell carcinoma treatment.

## History of Present Illness

Lucas Ramirez is a 55-year-old male diagnosed with Stage III renal cell carcinoma in September 2022. He underwent radical nephrectomy followed by adjuvant immunotherapy with nivolumab and ipilimumab, completed in June 2023.

## Past Medical History

- Hypertension
- Hyperlipidemia

## Medications

- Nivolumab:** Completed 12 cycles, last dose May 2023
- Ipilimumab:** Completed 4 cycles, last dose June 2023
- Losartan:** 50 mg PO QD
- Atorvastatin:** 20 mg PO QD

## Review of Systems

- Constitutional:** No weight loss, no fatigue
- Cardiovascular:** No chest pain, no palpitations
- Endocrine:** Blood pressure controlled

## Physical Examination

- **General:** Alert, oriented, no acute distress
- **Vital Signs:** BP 130/80, HR 70, RR 16, Temp 98.2°F
- **Abdomen:** No tenderness, no masses
- **Cardiovascular:** Regular rate and rhythm, no murmurs

## Assessment

- **Stage III renal cell carcinoma, post-surgical and immunotherapy**
- **No evidence of recurrence**

## Plan

1. Surveillance with abdominal CT scan in 6 months.
2. Routine blood tests including renal function panel in 3 months.
3. Follow up in 6 months for routine check-up and review of labs.

### Signed:

Dr. Emma Foster, MD

Oncologist, Vita Clinic

[emma.foster@vitaclinic.com](mailto:emma.foster@vitaclinic.com)